The document discusses anatomical variations of the radial artery that can cause failures in transradial interventions, techniques to manage arterial spasm and loops during the procedure, and evidence that the radial approach has better outcomes than femoral especially in STEMI patients while emphasizing the need for dedicated equipment and techniques to minimize complications.
Significant, defined as a greater than 50 percent narrowing, left main coronary artery disease is found in 4 to 6 percent of all patients who undergo coronary arteriography. When present, it is associated with multivessel coronary artery disease about 70 percent of the time
Significant, defined as a greater than 50 percent narrowing, left main coronary artery disease is found in 4 to 6 percent of all patients who undergo coronary arteriography. When present, it is associated with multivessel coronary artery disease about 70 percent of the time
The prevalence of degenerative valvular disease is increasing in the context of an increasingly ageing population, and despite advances in medical and surgical interventions, is associated with a significantly worse outcome when compared with the general population. Data from the EuroHeart Survey (2003) suggests the commonest relates to native valve disease (predominantly aortic stenosis) however, more than one quarter of patients with valve disease have undergone a previous intervention. According to current guidelines, in general treatment for severe, symptomatic aortic stenosis is surgical aortic valve replacement, which is associated with excellent outcomes, however, despite this around 30% of such patients do not undergo surgical intervention.
The last decade has seen a significant change in the potential therapeutic options for patients with aortic valve disease due to the development of transcatheter techniques for valve implantation. Patented in 1991, the first successful human implant of a transcatheter aortic valve was undertaken in 2002, with currently >500,000 implantations having been undertaken in >70 countries worldwide. The evidence supporting transcatheter aortic valve implantation (TAVI) otherwise known as transcatheter aortic valve replacement (TAVR) came originally from the key PARTNER studies, where patients judged to have inoperable aortic stenosis who underwent TAVI having improved survival and a reduction in hospital admission at 1 year. Following the early safety and efficacy studies, and following increasing recommendations for TAVI as an option for patients at high risk in international guidelines, the use of transcatheter techniques is extending to those of lower risk.
An Overview of Filter-Protected Carotid Artery Stentinggailms
These slides give an overview of cerebral protection devices used today in carotid artery stenting, with special emphasis on distal protection filters. Previous work in the field, results from our laboratory, and future directions of device development are covered.
The prevalence of degenerative valvular disease is increasing in the context of an increasingly ageing population, and despite advances in medical and surgical interventions, is associated with a significantly worse outcome when compared with the general population. Data from the EuroHeart Survey (2003) suggests the commonest relates to native valve disease (predominantly aortic stenosis) however, more than one quarter of patients with valve disease have undergone a previous intervention. According to current guidelines, in general treatment for severe, symptomatic aortic stenosis is surgical aortic valve replacement, which is associated with excellent outcomes, however, despite this around 30% of such patients do not undergo surgical intervention.
The last decade has seen a significant change in the potential therapeutic options for patients with aortic valve disease due to the development of transcatheter techniques for valve implantation. Patented in 1991, the first successful human implant of a transcatheter aortic valve was undertaken in 2002, with currently >500,000 implantations having been undertaken in >70 countries worldwide. The evidence supporting transcatheter aortic valve implantation (TAVI) otherwise known as transcatheter aortic valve replacement (TAVR) came originally from the key PARTNER studies, where patients judged to have inoperable aortic stenosis who underwent TAVI having improved survival and a reduction in hospital admission at 1 year. Following the early safety and efficacy studies, and following increasing recommendations for TAVI as an option for patients at high risk in international guidelines, the use of transcatheter techniques is extending to those of lower risk.
An Overview of Filter-Protected Carotid Artery Stentinggailms
These slides give an overview of cerebral protection devices used today in carotid artery stenting, with special emphasis on distal protection filters. Previous work in the field, results from our laboratory, and future directions of device development are covered.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Evaluation of antidepressant activity of clitoris ternatea in animals
Hamon M 201111
1. From the wrist to the coronaries
Basics, Managing Loops, Tortuosity and Spasm
Martial HAMON, MD, FESC
CHU Caen, Cardiology
France
2. Disclosure Statement of Financial Interest
Affiliation/Financial Relationship
• Grant/Research Support:
GlaxoSmithKline, Lilly, The
Medicines Company.
• Consulting Fees/Honoraria:
Terumo, The Medicines Company,
Biotronik, Cordis, Medtronic.
www.angiosoft.net
3. Background
• The radial artery is increasingly used as a
preferred access route for PCI.
• Minimal vascular complications, immediate
ambulation, better post procedure comfort…
• Similar effectiveness in PCI and better outcomes in
STEMI patients
• A significant learning curve vs femoral procedures.
• Once the learning curve is passed, most TRl
procedure failures are due to anatomical variations
4. Are Radial Artery Anomalies a Major Cause of TRI Failure?
Multicentre prospective study from Dec 2005 to March 2007 in UK
Retrograde radial arteriography in all comers for a first radial procedure
Breakdown of anatomy and procedural outcome
Anatomical Findings No. of Patients % No. of P value
(n=1026) failure* (%)
Normal 871 84.9 8 (0.9) NA
Types of variations
High RA 80 7.8 4 (5.0) 0.415
bifurcation
RA loop 22 2.1 9 (40.1) <0.0001
RA tortuosity 25 2.4 6 (24.0) <0.001
UA anomaly 7 0.7 0 NA
Others 21 2.1 5 (23.8) <0.001
Total anomalies 155 15.1 24 (15.5) <0.0001
Lo TS and al. Heart 2009;95:410-415.
5. Normal Anatomy
BA
BA
RA
RA
UA
UA
Interosseous artery Interosseous & Median artery
12. Complex PCI and Radial Approach
Anatomic variations of radial artery, spasm
Subclavian artery and brachiocephalic trunk
Access Ascending aorta
Guiding Cath. back-up (EBU++)
Dedicated Curves
Deep cannulation (5 F++)
Guiding… ES wires, buddy wires
Left main disease
Proximal tortuosity, calcification
Intervention Side branch, second wire, kissing
Length, diameter
Caution in tortuous peripheral vasculature (Rota. or kissing )
Technical considerations Advanced TRI
13. Prevention of Arterial Spasm in TRI
The SPASM Study
1,219 consecutive patients randomized in 4 groups
Occurrence of radial Spasm (%)
22.2%
P<0.0001
13.3%
8.3% 7.9%
4.9%
Placebo Molsido. VerapamilVerapamil Verapamil
(n=198) 1 mg 2.5 mg 5 mg Molsido.
(n=203) (n=409) (n=203) (n=206)
Varenne O et al. Catheter Cardiovasc Interv. 2006;68:231-5
14. Minimizing radial artery injury
A randomized study 5F vs 6F
Dahm JB et al Cathet Cardiovasc Intervent 2002
15. Should Radial Access be the gold
standard in PCI?
Femoral: I C Future Recommendations ?
AHA/ACC/ESC
Radial: I A
I II III
Evidence &/or Conflicting Evidence Evidence &/or
Agreement Divergence of opinion Agreement
(Beneficial, Useful, Effective) (Usefulness, Efficacy) Not Useful/Effective
II a weight in favor Potentially Harmful
II b less well established
A. Multiple randomized trials or meta-analyses
B. Single randomized trial or non-randomized studies
C. Only consensus opinion of experts, case studies or standard of care
Hamon M, Nolan J. Heart 2009.
16. RIVAL
Primary and Secondary Outcomes
Radial Femoral
(n=3507) (n=3514) HR 95% CI P
% %
Primary Outcome
Death, MI, Stroke, 3.7 4.0 0.92 0.72-1.17 0.50
Non-CABG Major Bleed
Secondary Outcomes
Major Vascular Access
Site Complications 1.4 3.7 0.37 0.27-0.52 <0.0001
19. Summary-Conclusions
1. Expect anatomical variations
2. Over the wire exchange, never forced
3. Angiography if needed (anatomic variation)
4. Use dedicated material (needle, wires, sheaths..)
5. Spasm prevention & radial occlusion prevention
6. Minimize radial artery injury (5F, 6F, Sheathless
cath)
7. Consider alternative access in challenging cases
(Risk of stroke, radiation exposure)
8. Not a limitation in routine TRI